OSLO, Norway , Nov. 19, 2025 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study “Hexaminolevulinate-enhanced photodynamic diagnosis in the management of non-muscle-invasive bladder cancer (NMIBC): The influence […]
Tag: Photocure
Results for the third quarter of 2025
OSLO, Norway, Oct. 29, 2025 /PRNewswire/ — Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 134.1 million in the third quarter of 2025 (Q3 2024: NOK 120.1 million), and an EBITDA of NOK 10.2 […]
Results for the third quarter of 2025
OSLO, Norway, Oct. 29, 2025 /PRNewswire/ — Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 134.1 million in the third quarter of 2025 (Q3 2024: NOK 120.1 million), and an EBITDA of NOK 10.2 […]
Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy
OSLO, Norway, Oct. 15, 2025 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it has entered into a partnership with Intelligent Scopes Corporation (ISC) to develop Artificial Intelligence (AI) software with […]
Photocure establishes Named Patient Program to provide access to Hexvix in South Africa
OSLO, Norway, Sept. 27, 2024 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it entered into an agreement with Equity Pharmaceuticals PTY Limited, part of the Clinigen group, in September, to […]
